应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
STSA Satsuma Pharmaceuticals, Inc.
退市 05-02 05:24:01 EDT
1.10
+0.00
0.00%
最高
1.10
最低
1.10
成交量
0.00
今开
1.10
昨收
1.10
日振幅
0.00%
总市值
3,647万
流通市值
1,672万
总股本
3,315万
成交额
194.10万
换手率
0.00%
流通股本
1,520万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批
智通财经网 · 01-03
舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批
舒泰神(300204.SZ):STSA-1002注射液完成Ib/II期临床试验首例受试者给药
智通财经网 · 2023-12-11
舒泰神(300204.SZ):STSA-1002注射液完成Ib/II期临床试验首例受试者给药
舒泰神(300204.SZ):STSA-1301皮下注射液Ia期临床试验完成首例受试者给药
智通财经 · 2023-11-23
舒泰神(300204.SZ):STSA-1301皮下注射液Ia期临床试验完成首例受试者给药
加载更多
公司概况
公司名称:
Satsuma Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发一种治疗偏头痛急性治疗的新型治疗药物。
发行价格:
--
{"stockData":{"symbol":"STSA","market":"US","secType":"STK","nameCN":"Satsuma Pharmaceuticals, Inc.","latestPrice":1.1,"timestamp":1686168000000,"preClose":1.1,"halted":4,"volume":0,"delay":0,"floatShares":15203712,"shares":33152498,"eps":-1.999338,"marketStatus":"退市","marketStatusCode":1,"change":0,"latestTime":"05-02 05:24:01 EDT","open":1.1,"high":1.1,"low":1.1,"amount":1940959.886414,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.999338,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714656600000},"adr":0,"listingDate":1568347200000,"adjPreClose":1.1,"volumeRatio":0},"requestUrl":"/m/hq/s/STSA","defaultTab":"news","newsList":[{"id":"2400490844","title":"舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2400490844","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2400490844?lang=zh_cn&edition=full","pubTime":"2024-01-03 16:08","pubTimestamp":1704269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神 发布公告,近日,公司收到了国家药品监督管理局签发的STSA-1001注射液用于治疗癌痛的《药物临床试验批准通知书》,同意本品开展癌痛的临床试验。据悉,STSA-1001注射液是一种重组抗NGF的全人源IgG1单克隆抗体注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1049489.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2390133154","title":"舒泰神(300204.SZ):STSA-1002注射液完成Ib/II期临床试验首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2390133154","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2390133154?lang=zh_cn&edition=full","pubTime":"2023-12-11 17:15","pubTimestamp":1702286129,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神 公告,STSA-1002注射液完成了针对急性呼吸窘迫综合征Ib/II期临床试验的首例受试者给药。公告显示,STSA-1002是一种重组抗人补体蛋白C5a的全人源IgG1单克隆抗体。STSA-1002通过抑制C5a可有效阻断其对中性粒细胞的趋化、NETs形成、纤维蛋白生成;阻断中性粒细胞介导的免疫激活、对血管内皮和上皮细胞的破坏、血管通透性增加和凝血过程,从而阻断ARDS发生的上游机制,减轻ARDS的炎症反应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1036279.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2385164961","title":"舒泰神(300204.SZ):STSA-1301皮下注射液Ia期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2385164961","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2385164961?lang=zh_cn&edition=full","pubTime":"2023-11-23 16:27","pubTimestamp":1700728036,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神(300204.SZ)发布公告,公司于2023年10月收到了国家药品监督管理局签发的STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的《药物临床试验批准通知书》(通知书编号:2023LP02140),同意本品开展原发性免疫性血小板减少症的临床试验。近日,STSA-1301皮下注射液在首都医科大学附属北京地坛医院完成了针对原发性免疫性血小板减少症Ia期临床试验的首例受试者给药。公告称,本次取得STSA-1301皮下注射液Ia期临床试验完成首例受试者给药,不会对公司当前业绩产生重大影响。后续临床试验阶段是否顺利、能否获得生产批件、具备上市资格尚存在诸多不确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1028233.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.satsumarx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0.0577},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发一种治疗偏头痛急性治疗的新型治疗药物。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.18106},{"month":2,"riseRate":0.5,"avgChangeRate":-0.018348},{"month":3,"riseRate":0.25,"avgChangeRate":-0.137},{"month":4,"riseRate":0.5,"avgChangeRate":0.08762},{"month":5,"riseRate":0.25,"avgChangeRate":0.034529},{"month":6,"riseRate":1,"avgChangeRate":0.195405},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.113868},{"month":8,"riseRate":0.333333,"avgChangeRate":0.112636},{"month":9,"riseRate":0,"avgChangeRate":-0.31806},{"month":10,"riseRate":0.25,"avgChangeRate":-0.048014},{"month":11,"riseRate":0.5,"avgChangeRate":-0.101074},{"month":12,"riseRate":0.5,"avgChangeRate":0.052715}],"exchange":"NASDAQ","name":"Satsuma Pharmaceuticals, Inc.","nameEN":"Satsuma Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Satsuma Pharmaceuticals, Inc.,STSA,Satsuma Pharmaceuticals, Inc.股票,Satsuma Pharmaceuticals, Inc.股票老虎,Satsuma Pharmaceuticals, Inc.股票老虎国际,Satsuma Pharmaceuticals, Inc.行情,Satsuma Pharmaceuticals, Inc.股票行情,Satsuma Pharmaceuticals, Inc.股价,Satsuma Pharmaceuticals, Inc.股市,Satsuma Pharmaceuticals, Inc.股票价格,Satsuma Pharmaceuticals, Inc.股票交易,Satsuma Pharmaceuticals, Inc.股票购买,Satsuma Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}